Kinfo
Harrow Inc. logo

Harrow Inc.

HROWNASDAQHealthcare·US · USD
$30.52
-0.10 (-0.33%)
Prices as of October 8, 2026 · market closed

Price

Key statistics

Valuation
Market cap1.14B USD
Enterprise value1.36B USD
Trailing P/E-218.07
Forward P/E11.04
PEG ratio0.51
Price / sales4.17
Price / book75.42
Profitability
Gross margin71.27%
Operating margin-15.58%
Profit margin-13.51%
Return on assets-0.45%
Return on equity-116.07%
Income (TTM)
Revenue275.59M USD
Gross profit201.96M USD
EBITDA50.24M USD
Net income-37.23M USD
Diluted EPS-$0.98
Rev. growth (YoY)10.90%
Balance sheet
Total cash85.32M USD
Total debt300.74M USD
Debt / equity2,025.89
Current ratio2.24
Book value / share$0.41
Cash flow (TTM)
Operating cash flow6.25M USD
Levered free cash flow-5.49M USD
Shares & price
Shares outstanding37.48M
Float28.93M
Held by institutions58.58%
Beta0.19
50-day MA$36.82
200-day MA$40.21
52-week high$54.85
52-week low$28.54
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-10-0.24-0.46−91.67%2026-05-11-0.33-0.74−124.24%2026-03-020.480.27−43.75%2026-02-173.944.07+3.30%
About Harrow Inc.

Harrow Inc. is an eyecare pharmaceutical company that develops, manufactures, and commercializes ophthalmic products for the U.S. market. Its portfolio includes prescription and non-prescription therapies used by eye care professionals to manage conditions affecting the front and back of the eye, such as dry eye disease, glaucoma, cataracts, retinal disorders, allergies, and infections. Harrow operates through branded pharmaceuticals and ImprimisRx, its ophthalmology-focused compounding business, giving it a broad commercial footprint across eye care settings. The company’s products are used in physician offices, clinics, and surgical environments, supporting routine treatment as well as specialized ophthalmic care. Headquartered in Nashville, Tennessee, Harrow focuses on accessible eye care solutions and a product mix that spans branded, compounded, and other ophthalmic formulations.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Mark L. Baum J.D.
Employees
373
Headquarters
Nashville, TN, United States

Frequently asked questions about Harrow Inc.